Wave Life Sciences entered Phase 2a of its INLIGHT trial with WVE-007 carrying Phase 1 data showing visceral fat reduction and muscle preservation on what could eventually be a once or twice-yearly dosing schedule, a profile that sits in deliberate contrast to the daily or weekly administration required by approved GLP-1 therapies like semaglutide and tirzepatide. The Phase 2a cohort enrolling now targets a meaningfully heavier population, BMI 35 to 50 kg/m², compared to the Phase 1 average of roughly 32 kg/m², and includes participants with and without type 2 diabetes across U.S. and European sites. That enrollment expansion is not cosmetic. Testing at higher adiposity and with active comorbidities is where WVE-007 either earns or loses its claim to broad cardiometabolic relevance, since Phase 1 healthy volunteer data, however clean, do not move prescribers or payers on their own.
The trial’s endpoint battery is genuinely comprehensive: body weight, waist circumference, MRI and DEXA body composition, MRI-PDFF liver fat, HbA1c, and lipid panels over 12 months. That breadth reflects Wave’s intent to use INLIGHT Phase 2a as a simultaneous proof-of-concept for MASH and type 2 diabetes, not just obesity. Separately, the company plans to launch Phase 2 trials evaluating WVE-007 in combination with incretins and as a post-incretin maintenance strategy in the second half of 2026. The combination angle is strategically pointed: if WVE-007 can preserve muscle mass that GLP-1 agonists tend to erode, it has a biologically coherent role in a co-administration regimen rather than a purely competitive one. Arrowhead’s ARO-INHBE has produced early signals in the same INHBE silencing space, making the class increasingly crowded, but WVE-007’s SpiNA chemistry and dosing interval remain the differentiation story Wave is telling.
The RNA editing pipeline adds a second near-term regulatory inflection. Wave secured an FDA meeting, scheduled for late summer 2026, to discuss an accelerated approval pathway for WVE-006 in alpha-1 antitrypsin deficiency. RestorAATion-2 data through the 600 mg single-dose cohort show dose-dependent reductions in mutant Z-AAT protein with corresponding increases in wild-type M-AAT, recapitulating an MZ-like phenotype. Data from the 600 mg monthly multidose cohort, which will be the most commercially relevant readout, are expected in the second half of 2026. The FDA meeting outcome will determine whether that data package can support an accelerated approval filing or whether Wave needs a larger, longer study. Precedent from GalNAc-conjugated siRNA programs like vutrisiran demonstrates that infrequent subcutaneous dosing is achievable in clinical practice, lending credibility to Wave’s convenience argument for WVE-006.
With $490.6 million in cash and a runway extending into the third quarter of 2028, Wave is not financing against a near-term wall. The number to track is the outcome of that end-of-summer FDA accelerated approval meeting for WVE-006. A constructive response would compress the regulatory timeline for AATD substantially and validate RNA editing as a platform, pulling forward investor and partner attention to WVE-008 and the broader pipeline before any Phase 2a obesity data mature.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
